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ABSTRACT
Objective To study time trends in incidence of atrial 
fibrillation (AF) in the entire Norwegian population from 
2004 to 2014, by age and sex, and to estimate the 
prevalence of AF at the end of the study period.
Methods A national cohort of patients with AF (≥18 
years) was identified from inpatient admissions with 
AF and deaths with AF as underlying cause (1994–
2014), and AF outpatient visits (2008–2014) in the 
Cardiovascular Disease in Norway (CVDNOR) project. 
AF admissions or out- of- hospital death from AF, with 
no AF admission the previous 10 years defined incident 
AF. Age- standardised incidence rates (IR) and incidence 
rate ratios (IRR) were calculated. All AF cases identified 
through inpatient admissions and outpatient visits and 
alive as of 31 December 2014 defined AF prevalence.
Results We identified 175 979 incident AF cases (30% 
primary diagnosis, 69% secondary diagnosis, 0.6% out- 
of- hospital deaths). AF IRs (95% confidence intervals) 
per 100 000 person years were stable from 2004 (433 
(426–440)) to 2014 (440 (433–447)). IRs were stable or 
declining across strata of sex and age with the exception 
of an average yearly increase of 2.4% in 18–44 year- 
olds: IRR 1.024 (1.014–1.034). In 2014, the prevalence 
of AF in the adult population was 3.4%.
Conclusions We found overall stable IRs of AF for the 
adult Norwegian population from 2004 to 2014. The 
prevalence of AF was 3.4% at the end of 2014, which 
is higher than reported in previous studies. Signs of an 
increasing incidence of early- onset AF (<45 years) are 
worrying and need further investigation.
INTRODUCTION
Atrial fibrillation (AF) is an important prognostic 
indicator for stroke, heart failure, cardiovascular 
and all- cause mortality.1 The high mortality of 
patients with AF highlights the importance of 
disease surveillance for better healthcare resource 
allocation and for planning of preventive public 
health activities.
The reported incidence and prevalence of AF 
have been inconsistent across studies and coun-
tries, reflecting methodological differences making 
comparisons difficult.2 However, the majority 
of studies provide evidence of an increasing inci-
dence of AF in Western societies. In Olmsted 
County (Minnesota, USA), incidence rates of AF 
(inpatients and outpatients) increased from 1980 
to 2000 and then stabilised.3 4 In the Framingham 
Heart Study, incidence rates of AF (detected by all 
health data sources) increased from 1958 to 2007.5 
In Denmark, the incidence of AF causing hospital-
isation increased between 1983 and 2012,6 while 
in Iceland, incidence rates of AF (inpatients and 
outpatients) increased among women, but not men 
between 1991 and 2008.7 A pooled estimate of age- 
adjusted and sex- adjusted AF prevalence reported 
in population studies for the period 1968–2010 
suggested a prevalence of 2.8% in the adult popu-
lation. However, the estimates varied from 0.6% to 
6.6%, reflecting differences in the age distribution 
of the study populations: from 20 years and older 
to 65 years and older.8
We aimed to study trends in incidence of AF in 
Norway during 2004–2014, and to estimate the 
prevalence of AF, by age and sex.
METHODS
Data sources and data linkages
We used nationwide data on hospital visits and 
causes of death from the Cardiovascular Disease in 
Norway (CVDNOR) project.9 The data included 
time of admission and primary and secondary 
discharge diagnoses for all somatic inpatient 
hospital stays recorded in electronic patient admin-
istrative systems at all Norwegian hospitals during 
1994–2009 and in the Norwegian Patient Registry 
from 2008 to 2014. The data also included visits 
to hospital outpatient clinics and to physician 
specialist practices with reimbursement contracts 
with the public health authorities registered in the 
Norwegian Patient Registry (2008–2014). These 
data were linked with data from the Norwegian 
Cause of Death Registry (1994–2014) and data on 
vital status (alive, dead or emigrated) on 1 January 
each year from Statistics Norway (1994–2014). The 
linkage was performed by Statistics Norway, using 
the national personal identification number.
This research was done without patient 
involvement.
Identification of incident and prevalent AF cases
AF was defined by the International Classification 
of Diseases, 9th Revision (ICD-9) diagnosis code 
427.3 or ICD-10 diagnosis code I48 (including 
subcategories): AF and atrial flutter. AF cases 
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cases.10 11 The cohort of AF cases was identified from all inpa-
tient admissions with AF as primary or secondary diagnosis 
during 1994–2014 and from out- of- hospital deaths with AF as 
underlying cause, in the adult population ≥18 years.
Incident AF was defined as the first inpatient admission with 
AF or out- of- hospital death due to AF with no previous inpatient 
admission with AF noted in the past 10 years. For the incidence 
analyses, we defined inpatient admissions with a primary or 
secondary diagnosis of AF as hospitalised AF, and AF as under-
lying cause of death in the Cause of Death Registry without a 
registered hospitalisation for AF as out- of- hospital AF death. 
A 10- year washout period was applied to minimise misclassifi-
cation of recurrent cases as incident cases, while still allowing 
for a reasonably long study period. By this definition, less than 
5% of incident cases in 2014 were recurrent cases, that is, they 
had received an inpatient AF diagnosis before 2014, but more 
than 10 years ago. Corresponding numbers using 6- year, 7- year, 
8- year and 9- year washout periods were 15%, 11%, 9% and 7%, 
respectively.
In an analysis of the cumulative prevalence of AF from 1994 to 
2014, prevalent AF cases (primary or secondary diagnoses) were 
identified from inpatient admissions (1994–2014) and from 
visits to outpatient hospital clinics and to physician specialist 
practices (2008–2014). Prevalent AF cases at the end of 2014 
were defined as the total number of patients with at least one 
registered diagnosis of AF at an inpatient admission or outpa-
tient visit during 1994–2014 and alive as of 31 December 2014.
Study design
This was a nationwide cohort study. In analyses of AF incidence, 
the number of yearly incident cases of inpatient admission and 
out- of- hospital death from AF during 2004–2014 was the numer-
ator (online supplementary figure 1). The Norwegian popula-
tion free of AF (no inpatient admission for AF in the previous 
10 years) and aged ≥18 years on 1 January each year was the 
denominator. In the prevalence analysis, the number of preva-
lent AF cases alive as of 31 December 2014 was the numerator 
(online supplementary figure 2). The number of Norwegian resi-
dents aged ≥18 years as of 1 January 2015 was the denominator.
Comorbidity
In a supplementary analysis of inpatient admissions with incident 
AF, we assessed selected diagnoses co- occurring during the same 
admission and calculated the Charlson Comorbidity Index (CCI) 
using the coding algorithm and scoring suggested by Quan et al 
(online supplementary table 1).12 We selected diagnoses based 
on predisposing and reported comorbid conditions for AF and 
comorbidity groups from the CCI.6 12 13 In addition, we included 
the diagnosis of pneumonia and markers of frailty.
Sensitivity analysis
We assessed the stability over time in incident AF cases presenting 
at the hospital outpatient clinic as a proportion of all incident 
AF cases identified, during the period with available outpatient 
data from 2008 to 2014. Incident hospital outpatient AF cases 
were identified by the first visit to a hospital outpatient clinic 
with a diagnosis of AF and no inpatient admissions for AF in the 
previous 10 years.
Statistical methods
Age- standardised incidence rates with 95% confidence inter-
vals (CI) were calculated using direct standardisation with the 
age distribution of the Norwegian population free of AF as 
of 1 January 2004 (ie, individuals with no hospitalisation for 
AF during the previous 10 years) as standard population. Age- 
adjusted incidence rate ratios with 95% CI were estimated, using 
Poisson regression analyses with calendar year as a continuous 
covariate, expressed as average yearly change in incidence rates. 
Average yearly change in proportion with comorbidity among 
incident AF cases were estimated by risk ratios with 95% CI using 
binomial regression analyses with calendar year as continuous 
covariate. An interaction term between calendar year and sex 
was introduced to test potential sex- differences in time trends. 
Risk of comorbidity in men relative to women was assessed as 
risk ratios with 95% CI using age- adjusted binomial regression 
with sex as exposure variable. In addition to overall results, we 
report results stratified by sex and by age groups (18–44, 45–64, 
65–84 and ≥85 years). Stata V.15.0 (Stata, College Station, 
Texas, USA) software was used for all analyses.
RESULTS
Study population
We identified 175 979 cases with incident AF in Norway from 
2004 to 2014 (online supplementary figure 1). Of these, 30.0% 
had AF as the primary diagnosis at inpatient admission, 69.4% 
had AF as a secondary diagnosis at inpatient admission and 0.6% 
were out- of- hospital AF death cases. The proportion of inci-
dent cases with AF as the primary hospital discharge diagnosis 
increased from 2004 (27%) to 2014 (33%) overall and across all 
age and sex strata (online supplementary table 2).
Women accounted for 45% of the cohort of incident AF cases 
and had a higher mean age ± standard deviation at diagnosis 
(79.1±11.2) than men (72.1±13.0), both for primary and 
secondary AF diagnosis and over time (online supplementary 
table 3). Only 2% of the patients were younger than 45 years of 
age at diagnosis, 17% were 45–64, 55% were 65–84 and 26% 
were 85 years of age or older. The proportion of men was higher 
in all age groups except for the oldest group.
Comorbidity
Among hospitalised patients with AF as the primary diagnosis, 
12% had CCI score of ≥2 in contrast to 38% among those 
with AF as a secondary diagnosis. The most prevalent comorbid 
conditions at incident inpatient admission for AF were hyper-
tension (28%), coronary heart disease (25%), heart failure 
(21%) and pneumonia (13%). The majority of comorbidities 
were more common in men, especially co- occurring malignancy, 
renal disease and peripheral vascular disease. The exception was 
thyroid disorders, autoimmune diseases, hypertension, valvular 
heart disease, stroke, thromboembolism, dementia and frailty, 
which were more often present in women (online supplementary 
tables 4 and 5). The proportion with a CCI score ≥2 declined 
from 31% in 2004 to 28% in 2014 for all incident AF cases. A 
similar pattern was found for myocardial infarction, heart failure 
and diabetes, with somewhat more favourable decline over time 
in women than in men. For patients with AF as primary diag-
nosis, the proportion with co- occurring myocardial infarction 
increased and the proportion with heart failure was stable over 
time. In contrast, the co- occurrence of these conditions declined 
for patients with AF as secondary diagnosis (figure 1, online 
supplementary table 6).
Incidence
The age- standardised incidence rate of inpatient admission 
(primary or secondary diagnoses) or death from AF per 100 000 
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and 440 (95% CI 433 to 447) in 2014 (figure 2, table 1). On 
average, the total yearly incidence rate did not change markedly 
(−0.2%, 95% CI −0.3% to 0.0%, p=0.02). Consistent rates 
across all strata of age group and sex were observed with the 
exception of those aged 18–44 years where we observed a 2.4% 
(95% CI 1.4% to 3.4%, p<0.001) increase in the overall yearly 
incidence rate (women 2.1% (95% CI −0.1% to 4.3%, p=0.06), 
men 2.4% (95% CI 1.1% to 3.5%, p<0.001)) (figure 3, table 2).
The age- standardised incidence rate of inpatient admis-
sion with a primary diagnosis of AF per 100 000 person years 
increased from 117 (95% CI 113 to 120) in 2004 to 142 (95% 
CI 139 to 146) in 2014 (online supplementary figure 3 and 
table 3). The overall trend was a mean yearly increase of 1.9% 
(95% CI 1.7% to 2.2%, p<0.001). The increase was consistent 
in women (2.1% per year, 95% CI 1.7% to 2.6%, p<0.001) 
and men (1.6% per year, 95% CI 1.3% to 2.0%, p<0.001) and 
across age groups in both sexes, although the increase was small 
among those aged 45–64 years (online supplementary figure 4 
and table 7).
In analysis of incident cases with AF as a secondary diagnosis 
at inpatient admission, we observed a stable to slightly decreasing 
trend in the incidence rate per 100 000 person years, from 313 
(95% CI 308 to 319) in 2004 to 295 (95% CI 290 to 301) in 
2014 (online supplementary figure 5 and table 3). On average, 
the yearly decrease was 1.1% (95% CI 0.9% to 1.2%, p<0.001). 
This finding was consistent across sex and age groups, even 
though the estimates for those aged 18–45 years were imprecise 
(online supplementary figure 6 and table 7).
Cumulative prevalence
Since 1994, AF had been diagnosed during an inpatient admis-
sion or outpatient visit in 136 828 individuals (women: 55 440 
(41%); men: 81 388 (59%)) in Norway as of 31 December 
2014. This corresponds to a cumulative prevalence of 3.4% of 
the total Norwegian population ≥18 years (2.8% in women and 
4.0% in men) at the end of 2014. Figure 4 and table 3 show the 
prevalence by age for men and women.
Sensitivity analysis of outpatient visits
In total, 77 494 patients were registered with an AF diagnosis at 
one or more visits to a hospital outpatient clinic during 2008–
2014. The number of outpatients with no inpatient admission 
for AF in the preceding 10 years totalled 30 185, increasing from 
4041 in 2008 to 4895 in 2014, corresponding to 20% and 23% 
of all incident AF cases.
DISCUSSION
We observed stable age- standardised incidence rates of AF from 
2004 to 2014. The findings were generally consistent across sex 
and age groups except for a mean yearly increase of 2.4% in the 
youngest age group (18–44 years), which was most prominent 
among men. The cumulative prevalence of AF was 3.4% in the 
adult Norwegian population.
Temporal changes in coding practice, reimbursement rates, 
clinical guidelines, treatment strategies and handling of patients 
have to be taken into account when interpreting registry data 
from patient administrative systems. These changes may influ-
ence the preference of AF as primary or secondary diagnosis 
and could partly explain the decreased incidence of hospital-
isations with AF as a secondary diagnosis. Alternatively, the 
apparent decrease reflects the declining incidence rates of asso-
ciated conditions such as acute myocardial infarction and heart 
failure in Norway.14 15 Comorbidity burden and proportions 
with co- occurring myocardial infarction and heart failure for all 
incident AF cases in our study decreased over time, as previously 
shown.4–6 16–18 However, two population- based health examina-
tion surveys found stable rates of comorbid myocardial infarction, 
Figure 1 Proportions (%) with co- occurring myocardial infarction, 
diabetes, heart failure, hypertension and CCI score ≥2 reported at 
inpatient admission for incident AF from 2004 to 2014 in Norway, by 
year, sex and primary or secondary AF diagnosis. AF, atrial fibrillation; 
CCI, Charlson Comorbidity Index.
Figure 2 Age- standardised incidence rates with 95% CI of atrial 
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more in agreement with the novel finding from our study of 
increasing proportions of co- occurring myocardial infarction 
for admissions with AF as primary diagnosis.4 5 In contrast to 
our study, a Danish registry study reported lower, but increasing 
levels of comorbidity burden over time.6 Of interest, we found 
higher comorbidity in men with more co- occurring malignancy, 
renal disease and peripheral vascular disease, whereas women 
who were older had more often dementia, frailty and autoim-
mune disease. We also found that men had more co- occurring 
coronary heart disease and women more hypertension, thyroid 
disorders and stroke, similar to previous reports.5 16
Detection of AF has possibly increased during the study period 
due to increased awareness of AF and its complications among 
clinicians and in the population.1 5 Furthermore, it has been 
Table 1 Age- standardised incidence rates of inpatient admission or death from atrial fibrillation per 100 000 person years in Norway 2004–2014 
by year, sex and age group
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Men
18–44 years
  Incidence rate 26 31 31 33 36 30 29 36 36 37 35
  Cases 225 267 268 287 322 275 264 330 339 346 335
45–64 years
  Incidence rate 306 314 336 323 316 302 320 313 316 328 291
  Cases 1696 1797 1983 1987 2000 1958 2069 2044 2086 2170 1939
65–84 years
  Incidence rate 2147 2238 2249 2261 2187 2073 2231 2158 2286 2158 2125
  Cases 4774 4986 4963 4986 4851 4657 5079 4993 5455 5273 5335
≥85 years
  Incidence rate 5484 6531 6353 5956 6413 6207 6436 6232 6068 6006 6195
  Cases 1192 1458 1468 1421 1548 1536 1637 1600 1603 1596 1691
All ages
  Incidence rate 576 620 624 614 612 582 617 602 620 602 589
  Cases 7887 8508 8682 8681 8721 8426 9049 8967 9483 9385 9300
Women
18–44 years
  Incidence rate 7 8 8 8 9 10 9 9 11 8 9
  Cases 61 71 69 68 77 84 81 77 100 74 84
45–64 years
  Incidence rate 108 118 108 115 120 105 106 104 109 109 105
  Cases 601 675 648 710 766 685 701 694 717 717 695
65–84 years
  Incidence rate 1241 1244 1248 1226 1235 1205 1204 1220 1280 1212 1231
  Cases 3996 3975 3908 3772 3750 3633 3613 3681 3915 3748 3851
≥85 years
  Incidence rate 4063 4357 4592 4369 4263 4088 4074 4118 4042 4141 4066
  Cases 2299 2487 2719 2650 2642 2575 2619 2656 2633 2673 2640
All ages
  Incidence rate 327 338 341 335 336 323 322 325 335 325 326
  Cases 6957 7208 7344 7200 7235 6977 7014 7108 7365 7212 7270
Total
18–44 years
  Incidence rate 17 20 20 21 23 20 19 22 24 23 23
  Cases 286 338 337 355 399 359 345 407 439 420 419
45–64 years
  Incidence rate 207 216 222 219 218 204 213 209 213 219 199
  Cases 2297 2472 2631 2697 2766 2643 2770 2738 2803 2887 2634
65–84 years
  Incidence rate 1620 1663 1670 1666 1643 1582 1648 1625 1717 1624 1622
  Cases 8770 8961 8871 8758 8601 8290 8692 8674 9370 9021 9186
≥85 years
  Incidence rate 4458 4980 5088 4824 4866 4685 4750 4718 4636 4693 4729
  Cases 3491 3945 4187 4071 4190 4111 4256 4256 4236 4269 4331
All ages
  Incidence rate 433 456 462 455 453 433 447 443 458 446 440
  Cases 14 844 15 716 16 026 15 881 15 956 15 403 16 063 16 075 16 848 16 597 16 570
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suggested that increased incidence rates may partly arise due 
to improvements in surveillance methods (new modalities for 
short- term and long- term ECG monitoring) and their increased 
use in different patient groups (eg, poststroke ECG screening). 
In the population- based Framingham Heart Study, incidence 
rates of AF detected by all health data sources increased from 
1958 to 2007, yet the rate of AF detected by ECG at repeated 
study visits did not increase during this period.5
Our results suggested a shift over time in referral practice to 
more outpatient treatment for new patients with AF, similar to 
reports from a Danish registry study.6 The described stable inci-
dence rates of AF may therefore have been increasingly under-
estimated and likely reflect an unbiased upward trend which 
supports the observation that incidence rates have not decreased.
Changes in AF incidence over time are of clinical interest and 
need surveillance. Our observed increased incidence rate of AF in 
young adults is worrisome and requires further study of changes 
in underlying risk factors, primarily factors that impact younger 
birth cohorts born after the 1950s–1960s differently than older 
cohorts. In Norway, prevalence of obesity has increased over 
time, especially in the young adult population.19 In addition, the 
non- declining incidence rates of acute myocardial infarction in 
those below 45 years during 2001–2014 in Norway, could add 
to AF risk.14 Nevertheless, declining blood pressure has been 
observed in younger cohorts, which may lower the AF risk.20 
Increased awareness of obesity as an important modifiable risk 
factor in younger cohorts, as well as preventive measures that 
promote a stable or reduced body mass index over time, may 
reduce AF incidence.21
The reported incidence of AF has been inconsistent across 
published studies, depending on approaches used. In different 
US health registry databases, AF incidence rates increased from 
2001 to 200822 and from 2004 to 2016.23 In line with our 
finding of a stable incidence from 2004 to 2014, AF incidence 
rates increased from 1998 up to 2007 and then plateaued from 
2007 to 2010 in a UK primary care database linked with hospi-
talisation data.17 Incidence rates of AF in the Korean National 
Health Insurance database were stable from 2006 to 2015.24 In 
a Western Australian population, incidence rates of hospitalisa-
tions with AF as the primary diagnosis increased, whereas inci-
dence rates of hospitalisations with AF as any diagnosis decreased 
from 1995 to 2010, using a hospital admission database,18 in line 
with our findings.
In a systematic review, Ball et al8 estimated a pooled preva-
lence of 2.8% (95% CI 2.3% to 3.4%) in adults, 2.4% (95% 
CI 1.9% to 2.9%) in females and 3.3% (95% CI 2.7% to 4.0%) 
in males. Interestingly, we found a prevalence in Norway at the 
upper limit of these CIs, namely 3.4% in adults, 2.8% in women 
and 4.0% in men. To our knowledge, this is the highest nation-
wide prevalence reported to date. Based on inpatient and outpa-
tient hospital records, the prevalence was 2.9% in the Swedish 
adult population in 2010.25 A similar prevalence, 3.0%, was 
found in a smaller cohort in Northern Sweden in 2010, using 
hospital records and a regional ECG database.26
A major strength of our study is the use of nationwide data, 
and a long observation period, which in turn allow for an 
adequate washout period and enabled calculations of temporal 
trends of incidence. Our analysis of AF incidence is limited to 
inpatient admissions only as data from outpatient visits did not 
allow for an adequate washout period to define incident cases 
and were further limited by poor reporting: the proportion of 
Figure 3 Age- standardised incidence rates with 95% CI of atrial 
fibrillation per 100 000 person years from 2004 to 2014 in Norway by 
year, sex and age group.
Table 2 Average yearly change in incidence rates of inpatient 
admission or death from atrial fibrillation in Norway 2004–2014 by sex 
and age group




  18–44 years 3258 1.024 (1.013 to 1.035) <0.001
  45–64 years 21 729 0.996 (0.992 to 1.000) 0.062
  65–84 years 55 352 0.998 (0.995 to 1.001) 0.117
  ≥85 years 16 750 1.000 (0.995 to 1.005) 0.987
  All ages 97 089 0.999 (0.997 to 1.001) 0.486
Women
  18–44 years 846 1.021 (0.999 to 1.043) 0.060
  45–64 years 7609 0.991 (0.984 to 0.998) 0.016
  65–84 years 41 842 0.999 (0.996 to 1.002) 0.439
  ≥85 years 28 593 0.995 (0.991 to 0.998) 0.004
  All ages 78 890 0.994 (0.992 to 0.997) <0.001
Total
  18–44 years 4104 1.024 (1.014 to 1.034) <0.001
  45–64 years 29 338 0.995 (0.991 to 0.999) 0.009
  65–84 years 97 194 0.999 (0.998 to 1.001) 0.611
  ≥85 years 45 343 0.998 (0.995 to 1.001) 0.132
  All ages 175 979 0.998 (0.997 to 1.000) 0.020
Figure 4 Cumulative prevalence of atrial fibrillation from 1994 to 
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specialists that reported their activity to the Norwegian Patient 
Registry was 56% in 2009.27 In addition, our definition of 
AF cases was based on inpatient hospital registry data and not 
verified by ECG or additional medical records. However, the 
validity of AF reported in Scandinavian studies has been high. 
Among patients with a hospital register- based AF diagnosis code, 
AF was confirmed by medical records or ECG from hospitals or 
primary care in 89%–97%.11 28 29 Another limitation is that we 
lacked data from primary care physicians and nursing homes to 
better estimate the true prevalence of AF. While we do not know 
the proportion of patients with AF in Norway that are treated 
only out- of- hospital, a study by Friberg et al25 suggested that 
22% of Swedish patients with AF were seen only in primary care 
practices. If we extrapolate this to our results, the prevalence of 
AF in the adult Norwegian population would be as high as 4.1%.
CONCLUSION
For the adult population in Norway, we found overall stable inci-
dence rates of AF from 2004 to 2014 and an AF prevalence of at 
least 3.4% at the end of 2014. Signs of increased incidence rates 
of early- onset AF (<45 years) are of concern and need further 
investigation.
Author affiliations
1Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, 
Oslo, Norway
2Department of Global Public Health and Primary Care, University of Bergen, Bergen, 
Hordaland, Norway
3Department of Neuromedicine and Movement Science, Norwegian University of 
Science and Technology, Trondheim, Norway
4Stroke Unit, Department of Internal Medicine, St. Olav’s Hospital, Trondheim, Norway
5Department of Medical Research, Vestre Viken Hospital Trust, Bærum Hospital, 
Gjettum, Norway
6Institute of Clinical Medicine, Department of Cardiology, University of Oslo, Oslo, 
Norway
7Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
8Department of Public Health and Nursing, Norwegian University of Science and 
Technology, Trondheim, Norway
9Department of Health Registries, Norwegian Institute of Public Health, Bergen, 
Norway
Acknowledgements The authors thank Tomislav Dimoski at The Norwegian 
Institute of Public Health for his contribution by developing the software necessary 
for obtaining data from Norwegian hospitals, conducting the data collection and 
quality assurance of data in tne CVDNOR project.
Contributors GST, IA, JI and RS planned the work. LJK, JI and IA had access to 
the data and contributed to the statistical analyses. LJK drafted the manuscript. 
All authors contributed to the design of the study, have critically revised the draft 
and have approved the final version of the submitted manuscript. LJK and IA are 
responsible for the overall content as guarantors.
Funding  Afib. no—the Norwegian Atrial Fibrillation Research Network—funded 
the project.
Competing interests MM reports personal fees from Boehringer- Ingelheim, 
personal fees from Bayer, personal fees from Bristol- Myers Squibb, personal fees 
from MSD, outside the submitted work. TB reports personal fees from Boehringer- 
Ingelheim, Bayer and Pfizer/Bristol- Myers Squibb, outside the submitted work. IEC 
reports personal fees from Merck, outside the submitted work.The other authors 
have nothing to disclose.
Patient and public involvement Patients and/or the public were not involved in 
the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Table 3 Cumulative prevalence of atrial fibrillation from 1994 to 2014 in Norway by age
Men Women Total
Age group, years Cases Population Prevalence, % Cases Population Prevalence, % Cases Population Prevalence, %
18–24 356 245 638 0.1 311 231 734 0.1 667 477 372 0.1
25–29 413 179 774 0.2 253 173 546 0.1 666 353 320 0.2
30–34 552 178 443 0.3 281 167 907 0.2 833 346 350 0.2
35–39 841 176 828 0.5 420 165 215 0.3 1261 342 043 0.4
40–44 1422 192 531 0.7 618 181 192 0.3 2040 373 723 0.5
45–49 2112 192 502 1.1 799 180 774 0.4 2911 373 276 0.8
50–54 3257 172 907 1.9 1154 163 707 0.7 4411 336 614 1.3
55–59 4996 160 450 3.1 1782 155 254 1.1 6778 315 704 2.1
60–64 7889 144 730 5.5 2944 142 764 2.1 10 833 287 494 3.8
65–69 12 292 138 419 8.9 5359 139 283 3.8 17 651 277 702 6.4
70–74 13 169 95 105 13.8 6734 101 758 6.6 19 903 196 863 10.1
75–79 12 000 63 154 19.0 7987 76 146 10.5 19 987 139 300 14.3
80–84 10 830 43 980 24.6 9588 61 543 15.6 20 418 105 523 19.3
85–89 7534 25 875 29.1 9577 45 535 21.0 17 111 71 410 24.0
90–94 3158 9881 32.0 6082 25 043 24.3 9240 34 924 26.5
95–99 524 1631 32.1 1402 6063 23.1 1926 7694 25.0
≥100 43 157 27.4 149 729 20.4 192 886 21.7
All ages 81 388 2 022 005 4.0 55 440 2 018 193 2.7 136 828 4 040 198 3.4
Key messages
What is already known on this subject?
 ► The reported incidence and prevalence of atrial fibrillation 
have been inconsistent across studies and countries.
What might this study add?
 ► The incidence rates of atrial fibrillation among adults in 
Norway were stable from 2004 to 2014, except for a possible 
increase in those less than 45 years. The prevalence of atrial 
fibrillation was 3.4% at the end of 2014.
How might this impact on clinical practice?
 ► A possible increase in early- onset atrial fibrillation incidence 





















7Kjerpeseth LJ, et al. Heart 2020;0:1–7. doi:10.1136/heartjnl-2020-316624
Arrhythmias and sudden death
Ethics approval The study was approved by the Regional Committee for Medical 
and Health Research Ethics, Health Region West (on 6 October 2009; reference 
number 2009/861) and complies with the Declaration of Helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available. The approval from the Ethics 
Committee does not include permission to make data materials available. LJK, JI and 
IA had full access to all the data in the study and takes responsibility for its integrity 
and the data analysis.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Lars Jøran Kjerpeseth http:// orcid. org/ 0000- 0002- 2033- 736X
Trygve Berge http:// orcid. org/ 0000- 0002- 7681- 8621
Inger Ariansen http:// orcid. org/ 0000- 0001- 8529- 4826
REFERENCES
 1 Kirchhof P, Benussi S, Kotecha D, et al. ESC guidelines for the management of atrial 
fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962.
 2 Yang P- S, Ryu S, Kim D, et al. Variations of prevalence and incidence of atrial 
fibrillation and oral anticoagulation rate according to different analysis approaches. 
Sci Rep 2018;8:6856.
 3 Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation 
in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for 
future prevalence. Circulation 2006;114:119–25.
 4 Chamberlain AM, Gersh BJ, Alonso A, et al. Decade- Long trends in atrial fibrillation 
incidence and survival: a community study. Am J Med 2015;128:260–7.
 5 Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, 
incidence, risk factors, and mortality in the Framingham heart study: a cohort study. 
Lancet 2015;386:154–62.
 6 Schmidt M, Ulrichsen SP, Pedersen L, et al. 30- Year nationwide trends in incidence of 
atrial fibrillation in Denmark and associated 5- year risk of heart failure, stroke, and 
death. Int J Cardiol 2016;225:30–6.
 7 Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence 
of atrial fibrillation in Iceland and future projections. Europace 2011;13:1110–7.
 8 Ball J, Carrington MJ, McMurray JJV, et al. Atrial fibrillation: profile and burden of an 
evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807–24.
 9 Igland J, Tell GS, Marta E, et al. The CVDNOR project: cardiovascular disease in 
Norway 1994-2009. Description of data and data quality 2013.
 10 Mareedu RK, Abdalrahman IB, Dharmashankar KC, et al. Atrial flutter versus atrial 
fibrillation in a general population: differences in comorbidities associated with their 
respective onset. Clin Med Res 2010;8:1–6.
 11 Rix TA, Riahi S, Overvad K, et al. Validity of the diagnoses atrial fibrillation and atrial 
flutter in a Danish patient registry. Scand Cardiovasc J 2012;46:149–53.
 12 Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities 
in ICD-9- CM and ICD-10 administrative data. Med Care 2005;43:1130–9.
 13 Allan V, Honarbakhsh S, Casas J- P, et al. Are cardiovascular risk factors also associated 
with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 
factors in 32 population- based cohorts of 20 million participants. Thromb Haemost 
2017;117:837–50.
 14 Sulo G, Igland J, Vollset SE, et al. Trends in incident acute myocardial infarction in 
Norway: an updated analysis to 2014 using national data from the CVDNOR project. 
Eur J Prev Cardiol 2018;25:1031–9.
 15 Sulo G, Igland J, Øverland S, et al. Heart failure in Norway, 2000-2014: analysing 
incident, total and readmission rates using data from the cardiovascular disease in 
Norway (CVDNOR) project. Eur J Heart Fail 2020;22:241–8.
 16 Frost L, Vestergaard P, Mosekilde L, et al. Trends in incidence and mortality in the 
hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int J Cardiol 
2005;103:78–84.
 17 Lane DA, Skjøth F, Lip GYH, et al. Temporal trends in incidence, prevalence, and 
mortality of atrial fibrillation in primary care. J Am Heart Assoc 2017;6:e005155.
 18 Briffa T, Hung J, Knuiman M, et al. Trends in incidence and prevalence of 
hospitalization for atrial fibrillation and associated mortality in Western Australia, 
1995-2010. Int J Cardiol 2016;208:19–25.
 19 Jacobsen BK, Aars NA. Changes in body mass index and the prevalence of obesity 
during 1994-2008: repeated cross- sectional surveys and longitudinal analyses. The 
Tromsø study. BMJ Open 2015;5:e007859.
 20 Hopstock LA, Bønaa KH, Eggen AE, et al. Longitudinal and secular trends in blood 
pressure among women and men in birth cohorts born between 1905 and 1977: the 
Tromsø study 1979 to 2008. Hypertension 2015;66:496–501.
 21 Ball J, Løchen M- L, Wilsgaard T, et al. Sex differences in the impact of body mass index 
on the risk of future atrial fibrillation: insights from the longitudinal population- based 
Tromsø study. J Am Heart Assoc 2018;7. doi:10.1161/JAHA.117.008414. [Epub 
ahead of print:
 22 Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence 
and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 
2013;112:1142–7.
 23 Williams BA, Honushefsky AM, Berger PB. Temporal trends in the incidence, 
prevalence, and survival of patients with atrial fibrillation from 2004 to 2016. Am J 
Cardiol 2017;120:1961–5.
 24 Kim D, Yang P- S, Jang E, et al. 10- Year nationwide trends of the incidence, prevalence, 
and adverse outcomes of non- valvular atrial fibrillation nationwide health insurance 
data covering the entire Korean population. Am Heart J 2018;202:20–6.
 25 Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 
2013;274:461–8.
 26 Norberg J, Bäckström S, Jansson J- H, et al. Estimating the prevalence of atrial 
fibrillation in a general population using validated electronic health data. Clin 
Epidemiol 2013;5:475–81.
 27 The Norwegian Patient Registry [in Norwegian. Oslo The Norwegian Diretcorate of 
Health; 2018.
 28 Smith JG, Platonov PG, Hedblad B, et al. Atrial fibrillation in the Malmö diet and 
cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J 
Epidemiol 2010;25:95–102.
 29 Malmo V, Langhammer A, Bønaa KH, et al. Validation of self- reported and hospital- 















eart: first published as 10.1136/heartjnl-2020-316624 on 20 A
ugust 2020. D
ow
nloaded from
 
